SAR448501

Phase 1Small molecule

Sanofi

SAR448501 is one of 82 small molecule programs targeting Rheumatic Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseActive, not recruiting

LymphomaActive, not recruiting

Rheumatic DiseasePhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 3

Nuvigil

NNuvo Research GmbH

Preclinical

1 4

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—8

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Lymphoma

NCT06392477

Q2 2029

Phase 1Recruiting

Rheumatic Disease

NCT06647069

Clinical

Trials by Indication[1]

Rheumatic Disease1 trial

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Recruiting· Sanofi logo

Sanofi·Phase 1·NCT06647069·62 enrolled

Lymphoma1 trial

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma

Recruiting· Sanofi logo

Sanofi·Phase 1·NCT06392477·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SAR448501. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR448501 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR448501. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

SAR448501

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Trials by Indication[1]

Rheumatic Disease1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News